Other equities analysts also recently issued reports about the company. Zacks Investment Research upgraded Kamada from a hold rating to a buy rating and set a $4.50 price target on the stock in a research note on Thursday, August 4th. HC Wainwright restated a buy rating and issued a $10.00 price target on shares of Kamada in a research note on Saturday, September 3rd. Finally, Jefferies Group restated a buy rating and issued a $7.00 price target on shares of Kamada in a research note on Wednesday, August 31st.
Kamada (NASDAQ:KMDA) opened at 5.04 on Monday. The company’s 50-day moving average price is $4.67 and its 200 day moving average price is $4.06. The stock’s market capitalization is $183.55 million. Kamada has a 52-week low of $3.24 and a 52-week high of $5.34.
Kamada (NASDAQ:KMDA) last issued its earnings results on Tuesday, August 2nd. The company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). Kamada had a negative return on equity of 10.59% and a negative net margin of 9.92%. The business had revenue of $19.10 million for the quarter, compared to the consensus estimate of $18.50 million. Equities analysts forecast that Kamada will post ($0.19) EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Kamada by 19.0% in the second quarter. Vanguard Group Inc. now owns 327,533 shares of the company’s stock worth $1,202,000 after buying an additional 52,195 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Kamada during the second quarter worth approximately $1,701,000. Finally, Renaissance Technologies LLC boosted its position in shares of Kamada by 2.4% in the first quarter. Renaissance Technologies LLC now owns 170,300 shares of the company’s stock worth $652,000 after buying an additional 4,000 shares in the last quarter. 5.31% of the stock is currently owned by institutional investors.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.